• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of wjgLink to Publisher's site
World J Gastroenterol. May 21, 2008; 14(19): 2986–2989.
Published online May 21, 2008. doi:  10.3748/wjg.14.2986
PMCID: PMC2712163

Mechanisms of biliary carcinogenesis and growth

Abstract

Cholangiocarcinoma is a rare cancer originating from the neoplastic transformation of the epithelial cells (i.e. cholangiocytes) that line the biliary tract. The prognosis for patients with cholangiocarcinoma is grim due to lack of viable treatment options. The increase in world-wide incidence and mortality from cholangiocarcinoma highlights the importance of understanding the intracellular mechanisms that trigger the neoplastic transformation of cholangiocytes and the growth of biliary cancers. The purpose of the following review is to address what has been learned over the past decade concerning the molecular basis of cholangiocarcinogenesis. The material presented is divided into two sections: (1) mechanisms regulating neoplastic transformation of cholangiocytes; and (2) factors regulating cholangiocarcinoma growth. An understanding of the growth regulatory mechanisms of cholangiocarcinoma will lead to the identification of therapeutic targets for this devastating cancer.

Keywords: Biliary carcinogenesis, Cholangiocarcinomas, Primary biliary cirrhosis, Primary sclerosing cholangitis

INTRODUCTION

Cholangiocytes are simple epithelial cells that line the intrahepatic biliary tract, which is a three-dimensional network of interconnecting ducts. The primary physiological function of cholangiocytes is the modification bile of canalicular origin and drainage of bile from the liver[1]. In addition to their role in the modification of ductal bile, cholangiocytes also participate in the detoxification of xenobiotics[1]. In recent years, interest in the study of cholangiocytes has increased dramatically due to a rise in the incidence of cholestatic liver diseases and biliary tract cancers (i.e. cholangiocarcinoma) in patients worldwide[25].

In diseases of the biliary tree (e.g. primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), liver allograft rejection and graft-versus-host disease), cholangiocytes are the primary target cells[1]. These cholangiopathies cause morbidity and mortality and are a major indication for liver transplantation[1]. In fact, these diseases contribute to 20% of the liver transplants in adults and 50% of those in pediatric patients[6]. Proliferation of cholangiocytes is critical for the maintenance of biliary mass and secretory function during the pathogenesis of chronic cholestatic liver diseases, such as primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Previous studies have demonstrated that proliferating cholangiocytes serve as a neuroendocrine compartment during liver disease pathogenesis and as such secrete and respond to a number of hormones and neuropeptides contributing to the autocrine and paracrine pathways that modulate liver inflammation and fibrosis, which are predicted to play key roles in cholangiocarcinogenesis[7].

Cholangiocarcinomas are adenocarcinomas that arise from the neoplastic transformation of cholangiocytes. Cholangiocarcinoma occurs in approximately 2 per 100 000 people and account for approximately 13% of primary liver cancers[4]. Cholangiocarcinomas can be divided into three categories based upon anatomic location: (1) intrahepatic cholangiocarcinoma, occurring in the bile ducts residing within the liver; (2) hilar cholangiocarcinoma, occurring at the confluence of the right and left hepatic ducts; and (3) distal extrahepatic bile duct cancers[8]. The prognosis for cholangiocarcinoma is grim due to lack of early diagnostic modalities and effective treatment paradigms. Cholangiocarcinomas are slow growing, metastasize late during the cancer’s progression, and present with symptoms of cholestasis due to the blockage of the bile duct by tumor growth[8]. In most cases, the tumors are well advanced at the time of diagnosis, which results in limited treatment options[9]. Many of these tumors are too advanced to be removed surgically and chemotherapy and radiation therapy usually are not effective, which indicates the dire need to understand the mechanisms that activate the neoplastic transformation of cholangiocytes and control the growth of cholangiocarcinomas.

RISK FACTORS FOR CHOLANGIOCARCINOMA

Several recent studies have shown that there is an increasing incidence of cholangiocarcinoma world-wide and in particular in Western countries, such as the United States, the United Kingdom, and Australia[4,1012]. Although most patients do not have identifiable risk factors for the disease, several risk factor have been established for cholangiocarcinoma[13]. The list of risk factors includes: gallstones or gallbladder inflammation, chronic ulcerative colitis, chronic infection of liver flukes, Clonorchis sinensis and Opisthorchis viverrini, and primary sclerosing cholangitis (PSC)[14]. In addition, a recent study revealed several novel risk factors for intrahepatic cholangiocarcinoma[15]. Hepatitis C virus infection, non-alcoholic fatty liver disease, obesity and smoking are all associated with intrahepatic cholangiocarcinoma[15]. The majority of these risk factors have the common features of chronic liver inflammation, cholestasis, and increased cholangiocyte turnover[16,17].

MOLECULAR MECHANISMS CONTRIBUTING TO CHOLANGIOCARCINOGENESIS

A common and important contributor to the malignant transformation of cholangiocytes is chronic inflammation of the liver. This inflammation is often coupled with the injury of bile duct epithelium and obstruction of bile flow, which increases cholangiocyte turnover (i.e. dysregulation in the balance of cholangiocyte proliferation and apoptosis)[9,18]. Persistent inflammation is thought to promote carcinogenesis by causing DNA damage, activating tissue reparative proliferation, and by creating a local environment that is enriched with cytokines and other growth factors[19]. Thereby, chronic inflammation creates local environmental conditions that are primed for cells to develop autonomous proliferative signaling by constitutive activation of pro-proliferative intracellular signaling pathways and enhanced production of mitogenic factors. Indeed recent studies have demonstrated that cholangiocytes release cytokines, such as interleukin 6 (IL-6), transforming growth factor-β (TGF-β), IL-8, tumor necrosis factor-α (TNF-α) and platelet–derived growth factor (PDGF). These factors can interact with cholangiocytes in an autocrine/paracrine fashion to regulate cholangiocyte intracellular signaling responses, which are thought to be altered during cholangiocarcinogenesis[20].

Cytokines activate inducible nitric oxide synthase (iNOS) in cholangiocytes. This results in the generation of nitric oxide, which along with other reactive oxygen species, may alter DNA bases, result in direct DNA damage and trigger the downregulation of DNA repair mechanisms[18]. Nitric oxide can directly or through the formation of peroxynitrite species can lead to the deamination of guanine and DNA adduct formation thereby promoting DNA mutations[18,21]. The resultant DNA damage leads to an increased mutation rate and alteration of genes critical to cell proliferation control. Consistent with this line of thought, activating mutations and the overexpression of EGFR, erb-2, K-ras, BRAF and hepatocyte growth factor/c-met (HGF) have been reported for cholangiocarcinoma. In addition, the proto-oncogene c-erbB-2 is activated in patients with cholangiocarcinoma[22,23]. Mutations affecting the promoter of the tumor suppressor p16INK4a that result in loss of transcription occur in both PSC and PSC-associated cholangiocarcinoma[24]. Alterations of p53, APC, and DPC4 tumor suppressor genes by a combination of chromosomal deletion, mutation, or methylation; and infrequently microsatellite instability have also been linked to cholangiocarcinoma[25]. In addition to increased ability of cholangiocytes to escape from senescence, activation of iNOS promotes the upregulation of COX-2 in immortalized mouse cholangiocytes suggesting that COX-2 and COX-2 derived prostanoids might play a key role in cholangiocarcinogenesis[26,27]. COX-2 also upregulated the expression of Notch, which has been implicated in other cancer types[27].

Cytokines, such as IL-6, appear to play an important role in cholangiocyte evasion of apoptosis. During the pathogenesis of cancer, the activation of evasion of apoptosis pathways helps to prevent cells with accumulating DNA damage from undergoing cell death pathways that normally eliminate such dysfunctional cells. Cholangiocarcinoma cells have been shown to secrete IL-6 and in an autocrine fashion IL-6 activates the pro-survival p38 mitogen activated protein kinase[28]. In fact, IL-6 upregulated the expression of myeloid cell leukemia-1 (Mcl-1) expression through STAT3 and AKT signaling pathways[29,30]. Mcl-1 is an anti-apoptotic protein in the Bcl-2 family of apoptotic proteins. Recently, the cellular expression of Mcl-1 has been shown to be controlled by the small endogenous RNA molecule, mir-29, which is down regulated in malignant cells consistent with Mcl-1 overexpression[31]. Enforced expression of mir-29 reduced Mcl-1 expression the malignant human cholangiocytes, KMCH[31]. Modulation of expression small endogenous RNAs such as mir-29 might represent a therapeutic paradigm for cholangiocarcinomas.

FACTORS REGULATING CHOLANGIOCARCINOMA GROWTH

A number of recent studies have shown that the nervous system, neuropeptides and neuroendocrine hormones play a key role in the modulation of cholangiocarcinoma growth[32]. We have demonstrated that proliferating cholangiocytes serve as a neuroendocrine compartment during liver disease pathogenesis and as such secrete and respond to a number of hormones and neuropeptides contributing to the autocrine and paracrine pathways that modulate liver inflammation and fibrosis[7]. The sympathetic nervous system has been shown to have a role in the negative regulation of cholangiocarcinoma growth[33]. The cholangiocarcinoma cell lines, Mz-ChA-1 and TFK-1, express the α2A-, α2B-, and α2C-adrenergic receptor subtypes[33]. Stimulation of the α2 receptors induced an upregulation of intracellular cAMP, which inhibited EGF-induced MAPK activity through an increase in Raf-1 and the sustained activation of B-raf, which resulted in the subsequent reduction of cholangiocarcinoma proliferation[33]. Although muscarinic acetylcholine receptor are expressed by cholangiocytes and play a role in regulating secretin-induced bile flow in rodents, the role of the parasympathetic nervous system has not been evaluated in cholangiocarcinoma and warrants consideration as a factor regulating cholangiocarcinoma growth[34,35].

Other neuroendocrine hormones and neurotransmitters have also been shown to play a role in the regulation of cholangiocarcinoma growth. The cholangiocarcinoma cell lines, Mz-ChA-1, HuH-28 and TFK-1, express the gastrin/CCK-B receptor and gastrin inhibits the proliferation and induces the activation of apoptosis in these cholangiocarcinomas through the activation of Ca2+-dependent PKC-α signaling. Most recently, Fava et al have shown that γ-aminobutyric acid (GABA) inhibits cholangiocarcinoma cell proliferation and migration[36]. This effect was also evident in vivo with GABA significantly decreasing the growth of cholangiocarcinoma tumor xenografts in nude mice[36].

Female steroid hormones, such as estrogens, have also been shown to play a role in the promoting of cholangiocarcinoma cell growth. 17-β estradiol stimulated the proliferation of human cholangiocarcinoma cells in vitro, which was blocked by tamoxifen[37]. Alvaro et al have demonstrated that human intrahepatic cholangiocarcinomas express the receptors for both estrogens and insulin-like growth factor (IGF-1)[38]. Their study indicates that estrogens and IGF-1 coordinately regulate cholangiocarcinoma growth and apoptosis[38].

Modulation of the endocannabinoid system is currently being targeted to develop possible therapeutic strategies for other cancer types. We recently demonstrated the novel finding that the two major endocannabinoids, anandamide and 2-arachidonylglycerol, have opposing actions on cholangiocarcinoma growth[39]. Interestingly, anandamide was found to be antiproliferative and to promote apoptosis, while, in contrast, 2-arachidonylglycerol stimulated cholangiocarcinoma cell growth[39]. Anandamide was shown to recruited Fas and Fas ligand into lipid rafts resulting in the activation of death receptor pathways and apoptosis in the cholangiocarcinoma cells[39].

CONCLUSION

Cholangiocarcinoma is a devastating neoplasm of the biliary tract that is increasing in incidence. While treatment options are limited, our knowledge base of the factors controlling cholangiocarcinogenesis and cholangiocarcinoma growth has greatly expanded in the past decade. These studies have clearly demonstrated that, during the course of chronic cholestasis and associated liver inflammation, a number of factors are released into the local environment that set into motion a series of events compound genomic damage leading to autonomous proliferation and escape from apoptosis (Figure (Figure1).1). Several potential areas seem promising for the development of prevention and treatment strategies for cholangiocarcinoma. In particular, inhibition of the COX-2 pathway during PSC warrants further investigation. Also, modulation of cholangiocarcinoma growth by the regulating neural imput or the endocannabinoid system might prove fruitful. Understanding the molecular mechanisms triggering biliary tract cancers will be key for the development of new treatments and diagnostic tools for cholangiocarcinoma.

Figure 1
Summary of key mechanisms regulating cholangiocarcinogenesis.

Supported by a grant award (#060483) to Dr. Glaser from Scott and White Hospital

Peer reviewer: Giammarco Fava, MD, Department of Gastroenterology, Università Politecnica delle Marche, Ancona, via Gervasoni 12, 60129 Ancona, Italy

S- Editor Liu Y L- Editor Negro F E- Editor Lu W

References

1. Alpini G, Prall RT, LaRusso NF. Philadelphia: Lippincott Williams & Wilkins; 2001. The pathobiology of biliary epithelia. The Liver; Biology & Pathobiology, 4E I M Arias, Boyer JL, Chisari FV, Fausto N, Jakoby W, Schachter D, and Shafritz D; pp. 421–435.
2. Roberts SK, Ludwig J, Larusso NF. The pathobiology of biliary epithelia. Gastroenterology. 1997;112:269–279. [PubMed]
3. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5:191–218. [PubMed]
4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10. [PMC free article] [PubMed]
5. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:33–42. [PubMed]
6. Annual Report of the US Organ Procurement. Transplan-tation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1991-2000
7. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, Alpini G. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology. 2007;132:415–431. [PubMed]
8. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856–867. [PMC free article] [PubMed]
9. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667. [PubMed]
10. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816–820. [PMC free article] [PubMed]
11. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813. [PubMed]
12. Davila JA, El-Serag HB. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol. 2002;97:3199–200. [PubMed]
13. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003;37:961–969. [PubMed]
14. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1–VI9. [PMC free article] [PubMed]
15. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221–1228. [PMC free article] [PubMed]
16. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol. 2002;17:1056–1063. [PubMed]
17. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17:1049–1055. [PubMed]
18. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184–190. [PubMed]
19. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83. [PubMed]
20. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis. 2004;24:127–137. [PubMed]
21. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology. 2001;120:190–199. [PubMed]
22. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36:439–450. [PubMed]
23. Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005;129:2047–2057. [PubMed]
24. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002;123:1090–1098. [PubMed]
25. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am. 2002;11:995–1009. [PubMed]
26. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol. 2004;287:G88–G95. [PubMed]
27. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology. 2005;128:1354–1368. [PubMed]
28. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30:1128–1133. [PubMed]
29. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005;42:1329–1338. [PubMed]
30. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054–2065. [PubMed]
31. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26:6133–6140. [PMC free article] [PubMed]
32. Marzioni M, Fava G, Benedetti A. Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol. 2006;12:3471–3480. [PMC free article] [PubMed]
33. Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H, Alpini G. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology. 2002;35:1329–1340. [PubMed]
34. Alvaro D, Alpini G, Jezequel AM, Bassotti C, Francia C, Fraioli F, Romeo R, Marucci L, Le Sage G, Glaser SS, et al. Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions. J Clin Invest. 1997;100:1349–1362. [PMC free article] [PubMed]
35. LeSagE G, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, Caligiuri A, Phinizy JL, Rodgers R, et al. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology. 1999;117:191–199. [PubMed]
36. Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 2005;65:11437–11446. [PubMed]
37. Sampson LK, Vickers SM, Ying W, Phillips JO. Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res. 1997;57:1743–1749. [PubMed]
38. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–888. [PMC free article] [PubMed]
39. DeMorrow S, Glaser S, Francis H, Venter J, Vaculin B, Vaculin S, Alpini G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem. 2007;282:13098–13113. [PubMed]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...